Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).
Oberender
H
H
Clinical Research, Schering AG, Berlin, Federal Republic of Germany.
Krais
T
T
Schäfer
M
M
Belcher
G
G
D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D011464:Epoprostenol / Q000627:therapeutic use*; D006801:Humans; D016285:Iloprost; D015337:Multicenter Studies as Topic; D011897:Random Allocation
D002317:Cardiovascular Agents; D011464:Epoprostenol; D016285:Iloprost